Studies show that Thealoz® Duo stabilizes the tear film. After 10 minutes, tear film thickness was increased by 40% more in a Thealoz® Duo group versus hyaluronate alone. And then in terms of how long it stayed on the eye, Thealoz® Duo maintained an increase in the tear film thickness for nearly four hours, six times longer than hyaluronate alone.
Inflammatory markers were also reduced. Tear levels of interleukins IL-1β, IL-6, and Il-8 were reduced by an average of 58% after just 2 months of treatment.
Symptoms are what patients complain about and there was a significant improvement in symptoms. After 5 weeks, 60% of patients had a reduction in moderate to severe OSDI scores, versus 36% using hyaluronate alone. And, interestingly, one out of four Thealoz® Duo patients were symptom-free versus one out of five using hyaluronate.
Watch below as Dr Clara Chan reviews the clinical data for Thealoz® Duo.
These are exciting times for those of us who treat dry eye disease. We are experiencing a dramatic shift in our understanding of the structure of tears and their role in the maintenance of the ocular ecosystem. In this presentation a leading expert reviews the latest insights into the development of artificial tears to manage this commonly seen condition.
The Evolution of Artificial Tears
This presentation on the modern management of dry eye disease and blepharitis was made by Clara C. Chan, MD, FRCSC, FACS, Assistant Professor at the University of Toronto Department of Ophthalmology and Vision Sciences, on July 14th 2021.
Watch the full webinar below.
Relieve dry eyes with the bioprotection and osmoregulation of Thealoz® Duo. Preservative- and phosphate-free, Thealoz® Duo is a unique dry eye treatment that restores the eye’s normal environment by combining the bioprotective properties of trehalose and the moisturizing effect of sodium hyaluronate.